Sino Biopharmaceutical Limited (SBHMY)
SBHMY Stock Price Chart
Explore Sino Biopharmaceutical Limited interactive price chart. Choose custom timeframes to analyze SBHMY price movements and trends.
SBHMY Company Profile
Discover essential business fundamentals and corporate details for Sino Biopharmaceutical Limited (SBHMY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Sept 2017
Employees
24.38K
Website
https://www.sinobiopharm.comCEO
S. Y. Tse
Description
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
SBHMY Financial Timeline
Browse a chronological timeline of Sino Biopharmaceutical Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 18 Mar 2026
Dividend declared on 19 Aug 2025
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend will be paid on 8 Oct 2025.
Earnings released on 11 Aug 2025
Dividend declared on 17 Jun 2025
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 25 Jul 2025.
Earnings released on 5 Jun 2025
Earnings released on 26 Mar 2025
EPS came in at $0.00 , while revenue for the quarter reached $889.68M .
Earnings released on 20 Mar 2025
EPS came in at $0.00 , while revenue for the quarter reached $925.73M .
Dividend declared on 11 Sept 2024
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 18 Oct 2024.
Earnings released on 13 Aug 2024
EPS came in at $0.01 , while revenue for the quarter reached $1.09B .
Dividend declared on 12 Jun 2024
A dividend of $0.08 per share was announced, adjusted to $0.08. The dividend was paid on 22 Jul 2024.
Earnings released on 8 Apr 2024
EPS came in at $0.01 , while revenue for the quarter reached $1.10B .
Earnings released on 28 Mar 2024
EPS came in at $0.00 , while revenue for the quarter reached $3.70B .
Dividend declared on 4 Oct 2023
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 13 Nov 2023.
Earnings released on 30 Jun 2023
EPS came in at $0.00 , while revenue for the quarter reached $1.05B .
Dividend declared on 20 Jun 2023
A dividend of $0.15 per share was announced, adjusted to $0.15. The dividend was paid on 31 Jul 2023.
Earnings released on 31 Mar 2023
EPS came in at $0.00 , while revenue for the quarter reached $1.11B .
Earnings released on 31 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $589.94M .
Earnings released on 30 Sept 2022
EPS came in at $0.00 , while revenue for the quarter reached $950.86M .
Dividend declared on 6 Sept 2022
A dividend of $0.15 per share was announced, adjusted to $0.15. The dividend was paid on 13 Oct 2022.
Earnings released on 30 Jun 2022
EPS came in at $0.01 , while revenue for the quarter reached $1.13B .
Dividend declared on 15 Jun 2022
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 27 Jul 2022.
Earnings released on 31 Mar 2022
EPS came in at $0.01 , while revenue for the quarter reached $1.20B .
Earnings released on 31 Dec 2021
EPS came in at $0.02 , while revenue for the quarter reached $982.01M .
Earnings released on 30 Sept 2021
EPS came in at $0.02 , while revenue for the quarter reached $968.98M .
Dividend declared on 10 Sept 2021
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 19 Oct 2021.
Earnings released on 30 Jun 2021
EPS came in at $0.05 , while revenue for the quarter reached $1.10B .
Dividend declared on 17 Jun 2021
A dividend of $0.10 per share was announced, adjusted to $0.10. The dividend was paid on 27 Jul 2021.
Earnings released on 31 Mar 2021
EPS came in at $0.02 , while revenue for the quarter reached $1.10B .
Earnings released on 31 Dec 2020
EPS came in at $0.01 , while revenue for the quarter reached $845.83M .
Dividend declared on 11 Dec 2020
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 15 Jan 2021.
Earnings released on 30 Sept 2020
EPS came in at $0.01 , while revenue for the quarter reached $806.04M .
Dividend declared on 11 Sept 2020
A dividend of $0.05 per share was announced, adjusted to $0.05. The dividend was paid on 15 Oct 2020.
Stock split effective on 4 Sept 2020
Shares were split 3 : 2 , changing the number of shares outstanding and the price per share accordingly.
SBHMY Stock Performance
Access detailed SBHMY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.